(Last updated : 2020-05-16 10:48:16)
  越智 宣昭
   Department     ,
   Position  
■ Journal
1. 2009/06 Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment 
2. 2010/02 Obstructive jaundice at the initial presentation in small-cell lung cancer 
3. 2015/01 Cisplatin-induced hyponatremia in malignancy:comparison between brand-name and generic formulation 
4. 2019/11/18 The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer  Link
5. 2019/08 The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer  Link
Display all(64)
■ Presentation
1. 2018/07/20 Patients with osteosarcoma and soft tissue sarcoma tend to become cancer refugees in
Japanese regional cities  
2. 2016/04/20 Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer  
3. 2015/10/08 Two Newly Discovered Mechanisms of Acquired Resistance to the Selective ALK Inhibitor Alectinib in Lung Cancer  
4. 2015/04/20 Both Programmed cell death protein 1 and programmed death-ligand 1 molecules can be expressed on the surface of small-cell lung cancer  
5. 2014/09/28 Acquired resistance to a new ALK inhibitor, alectinib in lung cancer  
Display all(19)